Advertisements


Aveo Pharmaceuticals jumps over 6% to $7.30 after tivozanib phase 3 update

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 19th, 2021

Aveo Pharmaceuticals presents new data from Phase 3 TIVO-3 trial of tivozanib

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 18th, 2019

Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

        - First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the Treatment of.....»»

Category: earningsSource: benzingaMay 14th, 2021

Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results

VICTORIA, BC, May 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug deli.....»»

Category: earningsSource: benzingaMay 13th, 2021

Reviva"s stock jumps after experimental schizophrenia drug meets endpoint in Phase 2 clinical trial

Shares of Reviva Pharmaceuticals Holdings Inc. soared 76.6% in trading on Monday after the company said its experimental treatment .....»»

Category: topSource: marketwatchApr 26th, 2021

Clovis jumps 20% to $6.39 per share after Phase 3 study update on Rubraca at SGO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 19th, 2021

Rhythm Pharmaceuticals to provide update on Phase 2 Basket study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 19th, 2021

Mid-Day Market Update: TriState Capital Jumps Following Q1 Results; Cyclacel Pharmaceuticals Shares Plunge

Midway through trading Tuesday, the Dow traded down 2.88% to 22968.65 while the NASDAQ fell 3.94% to 8223.52......»»

Category: earningsSource: benzingaApr 21st, 2020

Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update

– Topline data from Phase 3 NODE-301 trial of etripamil in pati.....»»

Category: earningsSource: benzingaMar 6th, 2020

Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update

– Topline data from Phase 3 NODE-301 trial of etripamil in patients with PSVT expected this month –  MONTREAL and CHARLOTTE, N.C., March 6,.....»»

Category: earningsSource: benzingaMar 6th, 2020

Aveo Pharmaceuticals appoints Erick Lucera as CFO amid coming tivozanib NDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 6th, 2020

Mid-Day Market Update: Neovasc Jumps After Submitting Approval Application For Neovasc Reducer; EyeGate Pharmaceuticals Shares Plummet

Midway through trading Tuesday, the Dow traded down 0.22% to 28398.61 while the NASDAQ fell 0.08% to 8938.93. The S&P also fell, dropping 0.16% to 3,216.21. 0 read more.....»»

Category: blogSource: benzingaDec 31st, 2019

Mid-Day Market Update: Cardlytics Jumps On Upbeat Q3 Results; Diffusion Pharmaceuticals Shares Plunge

Midway through trading Wednesday, the Dow traded up 0.04% to 27,701.84 while the NASDAQ fell 0.06% to 8,481.28. The S&P also rose, gaining 0.03% to 3,092.80. 0 read more.....»»

Category: blogSource: benzingaNov 13th, 2019

Mid-Day Market Update: Cardlytics Jumps On Upbeat Q3 Results; Diffusion Pharmaceuticals Shares Plunge

Midway through trading Wednesday, the Dow traded up 0.04% to 27,701.84 while the NASDAQ fell 0.06% to 8,481.28. The S&P also rose, gaining 0.03%.....»»

Category: earningsSource: benzingaNov 13th, 2019

Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

 -- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial.....»»

Category: earningsSource: benzingaNov 13th, 2019

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

 Positive Phase 2 IV ganaxolone data in RSE .....»»

Category: earningsSource: benzingaNov 6th, 2019

Aveo Pharmaceuticals provides update after FDA meeting discussing TIVO-3 results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 4th, 2019

Mid-Day Market Update: Achillion Pharmaceuticals Jumps Following Acquisition News; Natera Shares Plunge

Midway through trading Wednesday, the Dow traded up 0.07% to 27043.10 while the NASDAQ fell 0.24% to 8129.48. The S&P also fell, dropping 0.06% to.....»»

Category: earningsSource: benzingaOct 16th, 2019

Mid-Day Market Update: Achillion Pharmaceuticals Jumps Following Acquisition News; Natera Shares Plunge

Midway through trading Wednesday, the Dow traded up 0.07% to 27043.10 while the NASDAQ fell 0.24% to 8129.48. The S&P also fell, dropping 0.06% to 2,993.98. read more.....»»

Category: blogSource: benzingaOct 16th, 2019

Rhythm Pharmaceuticals to provide update on expanded Phase 2 Basket Study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 25th, 2019

Boston biotech Rhythm"s stock jumps on success of drug for rare form of obesity

Shares of Boston startup Rhythm Pharmaceuticals jumped 20 percent Wednesday after the company announced its drug for two genetic forms of obesity succeeded in a late-stage trial. In a phase 3 trial, Rhythm’s (Nasdaq: RYTM) drug setmelanotide was .....»»

Category: topSource: bizjournalsAug 7th, 2019